BSD Medical Reports Taiwan Food and Drug Administration Marketing and Import License Approval for the BSD-2000 is in Process

BSD Medical Corp., a provider of medical systems that utilize heat therapy to treat cancer, announced that BSD's exclusive Taiwan distributor, Linden Bioscience Co. has informed BSD that the Taiwan Food and Drug Administration (TFDA) marketing approval for the BSD- 2000 Hyperthermia System (BSD-2000) is in process and the import permit is expected to be issued in the near future.

Linden is a distributor of medical devices in Taiwan. Linden has committed to an initial purchase of four (4) BSD-2000 Hyperthermia Systems. BSD will commence shipping systems as soon as the import license is issued.

"We are excited to have the opportunity to start distributing the BSD-2000 Hyperthermia Systems in Taiwan," stated Tainang Huang, President of Linden. "We have worked closely with the TFDA on the marketing approval process so that we could capitalize on the large market for the BSD-2000 in Taiwan. We have already met with many prominent Taiwan physicians from several hospitals, including the very influential and largest hospital system in Taiwan, Chang Gung Memorial."

"We are pleased at the prospect of the TFDA import permit being issued and excited to work with such a prestigious Taiwanese company. We are confident in Linden's ability to make the BSD-2000 a success in Taiwan," stated Harold R. Wolcott, President and CEO of BSD Medical. "There is a substantial marketing opportunity for BSD's products in Taiwan, which is one of the most advanced medical device markets in Asia. The progress in Taiwan validates our efforts to expand our business in Asia."

Taiwan has a strong healthcare system that provides universal health insurance. Taiwan's medical device market is approximately $1.6 billion.

According to a release, the BSD-2000 - developed and patented exclusively by BSD - delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformite Europeenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.

More Information:

http://www.BSDMedical.com

((Comments on this story may be sent to [email protected]))